Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-NTP 15-5
- Development stage
- Phase 2
- Lead developer
- Jean Perrin Center at Clermont-Ferrand University Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
99mTc-NTP 15-5 is a technetium-99m labeled radiopharmaceutical developed as a diagnostic imaging agent for cartilage. It is a quaternary ammonium-polyglutamate derivative that specifically targets proteoglycans, particularly glycosaminoglycans (GAGs), within the extracellular matrix of cartilage. By binding to the negatively charged GAGs, the tracer enables the non-invasive assessment of cartilage integrity and proteoglycan content using Single Photon Emission Computed Tomography (SPECT) imaging. This is primarily intended for the early detection and monitoring of osteoarthritis, a condition characterized by the progressive loss of proteoglycans. The tracer was developed by the Centre Jean Perrin and has been evaluated in Phase I clinical trials for patients with knee osteoarthritis and breast cancer.
- Other names
- 99mTc-NTP15-599mTc-labeled quaternary ammonium-polyglutamate
02
Targets
ACAN (Aggrecan core protein)
Beyond the preview
Go deeper on 99mTc-NTP 15-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-NTP 15-5.